UBS Raises Price Target for Tenet Healthcare (THC) to $288 | THC Stock News

NodeGuardian · 2026-02-26T12:23:22+00:00

UBS has upgraded its rating for Tenet Healthcare (THC) to "Buy" with a price target increased to $288, reflecting analyst confidence. However, GuruFocus indicates potential downside risks, highlighting differing valuation views.

NodeGuardian

2026-02-26 12:23:22

Abstract generation in progress

UBS has re-affirmed its “Buy” rating for Tenet Healthcare (THC) and increased its price target to $288, up from $260, indicating strong confidence in the stock’s future. This adjustment aligns with a generally positive sentiment from several analysts who have recently raised their price targets for the Dallas-based healthcare services organization. Despite the positive analyst outlook, GuruFocus’s GF Value estimates a potential downside for THC, suggesting a divergence in valuation perspectives.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.